Literature DB >> 29159819

Focal Nodular Hyperplasia of the Liver: Contrast-Enhanced Ultrasonographic Features With Sonazoid.

Jongmee Lee1, Woo Kyoung Jeong2, Hyo K Lim2, Ah Young Kim2.   

Abstract

OBJECTIVES: To investigate ultrasonographic features of focal nodular hyperplasia of the liver with contrast-enhanced ultrasonography (CEUS) using Sonazoid (perflubutane; GE Healthcare, Oslo, Norway).
METHODS: Thirty-one patients with 31 focal nodular hyperplasia nodules who underwent CEUS using Sonazoid between July 2012 and February 2015 were included in this study. After the microbubble contrast agent was injected, intermittent CEUS images were obtained during the following 4 phases: arterial (10-40 seconds), portal venous (60-90 seconds), delayed (3 minutes), and Kupffer (>10 minutes). Three abdominal radiologists retrospectively reviewed the images and achieved consensus for vascular (central artery, stellate vascularity, and centrifugal enhancement) and dynamic enhancement patterns during the late arterial, portal venous, delayed, and Kupffer phases.
RESULTS: The patients included 12 men and 19 women (age range, 21-82 years; mean, 47 years). The mean diameter of the lesions ± SD was 2.2 ± 0.9 cm (range, 1.0-4.0 cm). On CEUS, 24 of 31 lesions (77.4%) showed central artery and stellate vascularity in the early arterial phase, and 25 (80.6%) showed centrifugal enhancement. Twenty-six lesions (83.9%) were hyperechoic during the late arterial phase and showed hyperenhancement or isoenhancement during the serial dynamic phases. Kupffer-phase images indicated that only 2 lesions (6.5%) were hypoechoic compared with surrounding liver parenchyma, whereas 29 (93.5%) remained either hyperechoic (2 [6.5%]) or isoechoic (27 [87.1%]).
CONCLUSIONS: Contrast-enhanced US using Sonazoid for focal nodular hyperplasia showed typical vascular patterns of central artery vascularity, stellate vascularity, and centrifugal enhancement. Most cases were either hyperenhanced or isoenhanced on serial dynamic- and Kupffer-phase imaging. Based on these results, CEUS can provide useful information for noninvasive focal nodular hyperplasia diagnoses.
© 2017 by the American Institute of Ultrasound in Medicine.

Entities:  

Keywords:  Sonazoid; abdominal; contrast-enhanced ultrasonography; focal nodular hyperplasia; hepatobiliary; liver neoplasms

Mesh:

Substances:

Year:  2017        PMID: 29159819     DOI: 10.1002/jum.14490

Source DB:  PubMed          Journal:  J Ultrasound Med        ISSN: 0278-4297            Impact factor:   2.153


  5 in total

Review 1.  Application of new ultrasound techniques for focal liver lesions.

Authors:  Feiqian Wang; Kazushi Numata; Hiromi Nihonmatsu; Masahiro Okada; Shin Maeda
Journal:  J Med Ultrason (2001)       Date:  2020-01-16       Impact factor: 1.314

2.  Surgical indications for focal nodular hyperplasia of the liver: Single-center experience of 48 adult cases.

Authors:  Jin-Min Jung; Shin Hwang; Ki-Hun Kim; Chul-Soo Ahn; Deok-Bog Moon; Tae-Yong Ha; Gi-Won Song; Dong-Hwan Jung
Journal:  Ann Hepatobiliary Pancreat Surg       Date:  2019-02-28

3.  Case Report: Rare Acute Abdomen: Focal Nodular Hyperplasia With Spontaneous Rupture.

Authors:  Ying Si; Bo Sun; Ting Zhao; Ke Xiao; Dong-Xia Zhao; Yong-Mao Huang
Journal:  Front Oncol       Date:  2022-07-13       Impact factor: 5.738

4.  Second-line Sonazoid-enhanced ultrasonography for Liver Imaging Reporting and Data System category 3 and 4 on gadoxetate-enhanced magnetic resonance imaging.

Authors:  Yeun-Yoon Kim; Ji Hye Min; Jeong Ah Hwang; Woo Kyoung Jeong; Dong Hyun Sinn; Hyo Keun Lim
Journal:  Ultrasonography       Date:  2022-01-28

5.  Prospective assessment of diagnostic efficacy and safety of SonazoidTM and SonoVue® ultrasound contrast agents in patients with focal liver lesions.

Authors:  Ke Lv; Hongyan Zhai; Yuxin Jiang; Ping Liang; Hui-Xiong Xu; Lianfang Du; Yi-Hong Chou; Xiaoyan Xie; YuKun Luo; Young Joon Lee; Jae Young Lee; Bing Hu; Baoming Luo; Yi Wang; Ying Luan; Christina Kalli; Kun Chen; Wenping Wang; Ja-Der Liang
Journal:  Abdom Radiol (NY)       Date:  2021-06-16
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.